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Abstract: An increasing number of untreatable infections are recorded every year. Many studies have
focused their efforts on developing new β-lactamase inhibitors to treat multi-drug resistant (MDR) iso-
lates. In the present study, sulbactam/avibactam and sulbactam/relebactam combination were tested
against 187 multi-drug resistant (MDR) Acinetobacter clinical isolates; both sulbactam/avibactam and
sulbactam/relebactam restored sulbactam activity. A decrease ≥2 dilutions in sulbactam MICs was
observed in 89% of the isolates when tested in combination with avibactam. Sulbactam/relebactam
was able to restore sulbactam susceptibility in 40% of the isolates. In addition, the susceptibility test-
ing using twenty-three A. baumannii AB5075 knockout strains revealed potential sulbactam and/or
sulbactam/avibactam target genes. We observed that diazabicyclooctanes (DBOs) β-lactamase in-
hibitors combined with sulbactam restore sulbactam susceptibility against carbapenem-resistant
Acinetobacter clinical isolates. However, relebactam was not as effective as avibactam when combined
with sulbactam. Exploring novel combinations may offer new options to treat Acinetobacter spp.
infections, especially for widespread oxacillinases and metallo-β-lactamases (MBLs) producers.
Keywords: Acinetobacter; carbapenem-resistance; sulbactam; avibactam; relebactam
1. Introduction
Infections caused by antibiotic-resistant bacteria are increasing in frequency, resulting
in significant patient morbidity and mortality [1,2]. Acinetobacter baumannii is a nosocomial
pathogen frequently resistant to multiple drugs. A. baumannii causes pneumonia, bac-
teremia, and wound infections with associated high mortality rates. The most problematic
strains are those resistant to carbapenems (carbapenem-resistant A. baumannii, CRAB). In
most cases, resistance is caused by either chromosomal or plasmid-mediated class D oxacil-
linases (blaOXA) [3–9], but recently, blaNDM-1 has also been increasingly observed [8,10–15].
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The advent of CRAB left few active antimicrobials, and unfortunately, these “last resort”
antibiotics (polymyxins, tigecycline, minocycline, and amikacin) are limited in efficacy
and toxic [16]. Interestingly, sulbactam, a β-lactamase inhibitor of Ambler class A en-
zymes, exhibits an inherent antibacterial activity against some bacterial species, including
Neisseria gonorrhoeae, Bacteroides fragilis, and Acinetobacter spp. [17]. Although ampicillin-
sulbactam effectively treated pneumonia, bacteremia, and other nosocomial infections
caused by A. baumannii, increasing resistance to this combination is becoming ever more
common [18–20].
Many recent studies focused on the development of new β-lactamase inhibitors to
treat multi-drug resistant (MDR) infections [21–28]. This research resulted in the design
of important types of β-lactamase inhibitors that include diazabicyclooctanes (DBOs)
and boronate-based compounds [25,29]. A promising DBO inhibitor is avibactam, a class
A and C β-lactamase inhibitor with some activity against class D enzymes (OXA-48-
like) [25,27,30,31]. While this inhibitor showed promising activity in combination with
ceftazidime to treat infections caused by pathogens with extreme resistance, it failed against
Acinetobacter [28]. In addition, a new FDA-approved DBO, relebactam, was effective in
combination with imipenem against KPC carbapenemases, AmpCs (class C), and/or
extended-spectrum β-lactamases (ESBLs) produced by Enterobacterales [24,26,30].
On the other hand, sulbactam combined with avibactam exhibited a synergistic activity
against class D carbapenemase-producing A. baumannii isolates [31]. Previous studies
evaluated the activity of sulbactam combined with other antibiotics [32–35]. However,
the performance of the combination of sulbactam with avibactam or relebactam against
carbapenem-resistant Acinetobacter is unknown. By interacting with multiple penicillin
binding proteins and β-lactamases, we hypothesized that the combination of sulbactam
and avibactam or relebactam further sensitizes A. baumannii and reduces MICs.
2. Results
Of the 187 selected Acinetobacter strains, including non-ESBL/non-CRAB (n = 4), ESBL
(n = 7 as follows, 5 PER-2, 1 VEB-1, 1 CTX-M-15), OXA-23 (n = 105), OXA-58 (n = 8),
OXA-143 (n = 2), ISAba1-blaOXA-66 (n = 1), IMP-1 (n = 12) and NDM-1 (n = 48) producers,
26/187 (14%) were inhibited by ≤4 mg/L of sulbactam alone. Only 10/116 (9%) of OXA
producers and none of the NDM producers were susceptible to sulbactam (MIC ≤ 4 mg/L)
(Figure 1A). Narrow-spectrum β-lactamases such as TEM-1, a common contributor to
sulbactam resistance in Acinetobacter (19), were detected only in 9 isolates; 8 isolates
also produced OXA-23 and one OXA-58. Co-production of ESBL among CRAB, another
attributable cause of sulbactam resistance, was observed in 17 isolates: PER-7 and PER-2
ESBL were detected among 14 NDM and 3 OXA-58 producers, respectively. The MICs of
sulbactam showed a bi-modal distribution with a first mode of 16 mg/L, corresponding
to OXA producers, and a second mode presumable above the highest evaluated value
(>64 mg/L) due to NDM producers (Figure 1A).
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Figure 1. MIC frequency distribution of sulbactam/avibactam, sulbactam/relebactam and sulbactam alone according
to the main resistance mechanism. Number of isolates with the indicated sulbactam (A) sulbactam/avibactam (B) or
sulbactam/relebactam (D) MIC value, according to the resistant mechanisms. No. isolates with the indicated concentration
decrease in sulbactam MIC by addition of avibactam (C) or relebactam (E) according to the resistant mechanisms. The
dotted line indicates the breakpoint value that defines susceptible/resistant (A,B,D) according to definitions.
2.1. Sulbactam/Avibactam Susceptibility Testing of Acinetobacter spp. Clinical Strains
We observed that 129/187 (69%) Acinetobacter spp. isolates were inhibited by 4 mg/L of
sulbactam when combined with 4 mg/L avibactam (Figure 1B). Remarkably, 105/116 (91%)
of OXA producers showed MIC equal to or less than 4 mg/L for the sulbactam/avibactam
combination. NDM producers showed a reduction in the MICs of sulbactam due to the
addition of avibactam, although MIC values were above 4 mg/L for all but one isolate
(Figure 1B). The MICs of sulbactam/avibactam also showed a bi-modal distribution but
with its modes displaced toward lower MICs. The first mode of 2 mg/L (3-fold lower when
compared to sulbactam alone) corresponded to OXA producers, and the second mode of
32 mg/L to NDM producers. The MIC50 and MIC90 of sulbactam/avibactam were 2 and
4 mg/L for OXA producers compared to 16 and 64 mg/L for sulbactam alone, respectively.
Among NDM producers, the MIC50 and MIC90 values of >64 mg/L for sulbactam alone
decreased to 32 and 64 mg/L for sulbactam/avibactam, respectively. An experiment using
an expanded range of concentrations using as highest value 1024 mg/L on a subset of NDM
producers (n = 40/48) showed an MIC50 of 256 mg/L for sulbactam alone and 32 mg/L
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for sulbactam/avibactam. This result indicated that there is an enhancement of sulbactam
activity by avibactam in this group of strains.
The average sulbactam MIC decrease (range) by avibactam was: 3-fold decrease (0–5)
for non-ESBL/non-CRE, 4-fold decrease (2–9) for ESBL, 3-fold decrease (0–7) for OXA-23,
2.4-fold decrease (2–7) for other OXAs, 2.4-fold decrease (1–5) for IMP-1 and 2-fold decrease
(0–4) for NDM producers (Figure 1C).
A total of 159 (89%) of the strains showed an equal or greater than twofold decrease
in the sulbactam MIC by avibactam: 32/40 (80%) NDMs, 11/12 (92%) IMP-1, 106/116
(91%) OXAs, 7/7 (100%) ESBL and 3/5 (60%) non-ESBL/non-CRAB (Figure 1C). Sulbactam
enhanced activity by avibactam was confirmed in selected strains by gradient diffusion
method (E-test) with commercial sulbactam strips (Liofilchem) supporting the previous
observation (Figure 2).
Figure 2. Gradient diffusion (E-test) of sulbactam/avibactam (MH + AVI) and sulbactam (MH) in selected
representative strains.
Among OXA-producers, only one A. baumannii OXA-23 (M15094/AMA116) showed
identical MIC values for sulbactam alone and sulbactam/avibactam (MIC 16 mg/L). Other
8 OXA-producers (7 A. baumannii and 1 A. sp. genomospecies 10) exhibited a 1 dilution
decreased in sulbactam MIC by avibactam: 3 isolates already susceptible to sulbactam
alone (OXA-58) and 5 resistant isolates (OXA-23).
2.2. Sulbactam/Relebactam Susceptibility Testing of Acinetobacter spp. Clinical Strains
With the sulbactam/relebactam combination, 73/187 (39%) Acinetobacter spp. isolates
were inhibited by 4 mg/L (Figure 1D). The difference in activity with avibactam was
due to a smaller proportion of OXA producers (52/116, 45%) inhibited with the combi-
nation of sulbactam/relebactam (Figure 1E). All 9 Acinetobacter isolates producing class
D β-lactamases that were not inhibited by avibactam/sulbactam were also resistant to
avibactam/relebactam. The MICs of sulbactam/relebactam also showed a bi-modal dis-
tribution with MIC50 and MIC90 of sulbactam/relebactam of 8 and 16 mg/L for OXA
producers compared to 16 and 64 mg/L for sulbactam alone. Among NDM producers,
the MIC50 values were 64 mg/L for sulbactam/relebactam alone compared to 256 mg/L
for sulbactam.
For strains harboring MBLs, colistin and tigecycline were the only tested comparators
with uniform in vitro activity (100% and 94% susceptible, respectively). Only 18% of
NDM producers were susceptible to amikacin. Conversely, comparators among OXA
producers were less active than the sulbactam/avibactam combination: 86% and 85% of
susceptibility to colistin and tigecycline, respectively. Ceftazidime was only active against
non-ESBL/non-CRAB isolates, while ceftazidime/avibactam was not active against CRAB
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and showed a modest 14% susceptibility against ESBL producers. Imipenem was uniformly
active against non-CRAB isolates, but only 2% of CRABs (all OXA-58 producers) were
susceptible to this carbapenem.
2.3. Sulbactam/Avibactam Susceptibility Testing of A. baumannii Knockout Strains
The potentiation of sulbactam activity by avibactam was observed in carbapenemases
refractory to DBOs inhibition, as OXAs commonly found in Acinetobacter, suggesting a
mode of action in these species unrelated to the reported inhibitory capacity. To reveal
the potential sulbactam/avibactam targets, twenty-three A. baumannii AB5075 knockout
strains were tested to identify potential sulbactam/avibactam targets. Knockout mutant in
genes related with efflux pumps, two components system, cell wall synthesis genes, among
others, were used. A. baumannii AB5075 MIC to sulbactam was 24 mg/L and showed a
16 times reduction in sulbactam MIC by addition of avibactam (Table 1).
Table 1. Sulbactam MICs against knockout A. baumannii strains using Mueller–Hinton agar with and
without avibactam supplementation.

























The results observed with A. baumannii AB5075 mutants can be classified into three
large groups.
i. Mutations affecting the activity of sulbactam alone: when comparing sulbactam MIC
in the wild-type strains and isogenic mutants, a decrease in MIC values from 24 to
3 mg/L was observed in the AB5075∆mrcB and AB5075∆mreB, suggesting a potential
role in sulbactam susceptibility (interaction). The mrcB and mreB genes, which code
for a transglycosylase-transpeptidase and a cytoskeletal protein, respectively, were
previously reported as genes involved in the formation of the peptidoglycan synthesis.
Potentiation of sulbactam activity by avibactam is also lost in these mutant strains.
Additionally, the A. baumannii AB5075∆PBPG MIC of sulbactam is 1.5-fold lower
than that measured for A. baumannii AB5075. PBPs are known to be sulbactam
targets [36]. Previous reports demonstrated that the antibacterial activity of sulbactam
was mediated through inhibition of PBP1 and PBP3.
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ii. Mutations that result in loss of avibactam enhancement of sulbactam activity: a 1 or
0-fold decrease in the MIC values comparing sulbactam with sulbactam/avibactam
MICs was observed in seven A. baumannii knockout strains (AB5075∆bfmR, AB5075∆P
BPG, AB5075∆advA, AB5075∆adeB, AB5075∆mrcB, AB5075∆xerD, and AB5075∆mreB).
These results identified potential sulbactam and/or sulbactam/avibactam targets
(Table 1).
iii. Mutations that do not affect susceptibility to sulbactam or potentiation of sulbactam
by avibactam: ≤2-fold decrease in the MIC was observed in twelve A. baumannii
AB5075 knockout strains comparing sulbactam with sulbactam/avibactam MIC. We
can rule out that these mutated genes are involved in the mechanisms of action (or
interaction) of sulbactam and avibactam.
3. Discussion
Infections with the hospital-acquired bacterium Acinetobacter are extremely difficult to
treat. While the development of new antibiotics remains one option in the fight against
strains resistant to those currently available, an attractive (and faster) alternative is the
development of adjuvant therapies to restore the efficacy of existing antibiotics. A pre-
liminary in vitro study has shown promising results with avibactam adjuvant approaches
combined with sulbactam [31]. In this work we contributed new knowledge to support
sulbactam/avibactam interaction.
We observed that the addition of DBOs restores sulbactam susceptibility. This interac-
tion between DBOs and sulbactam presented the following characteristics: (i) was more
potent in serine carbapenemase-producing strains, such as oxacillinases, but it was also
manifested to a lesser extent in NDM-producing strains; (ii) was not related to the DBO
concentration as a dose–response relationship was not observed in MICs when both DBOs
were tested using twice the recommended concentration (8 mg/L) (not shown); (iv) was
not related to the β-lactamase inhibitory capacity described for DBOs; and (v) avibactam
was more potent in restoring sulbactam susceptibility than relebactam. The differences
observed between avibactam and relebactam would support these hypotheses, the larger
molecular size of the second DBO (molar mass 265.24 g/mol g·mol−1 vs. 348.37 g·mol−1,
respectively) could be responsible for a reduced capability to penetrate the outer membrane
and reach its targets.
Recently, ETX2514, named durlobactam, a new DBO inhibitor derived from avibactam
(resulting from the addition of a double bond between C3 and C4 and a methyl group in C3
position compared to avibactam), significantly increased the susceptibility of Acinetobacter
clinical isolates when it was combined with sulbactam [22]. Sulbactam/durlobactam has
an MIC50/MIC90 of 1 and 2 mg/L against a global collection of strains. These values are
comparable to those obtained in this work for the sulbactam/avibactam combination for
OXA-23 producers (2 and 4 mg/L, respectively) [22]. However, the combination with
durlobactam was not effective for NDM strains with MIC50/90 comparable to those of
sulbactam alone, unlike avibactam, which showed a slight improvement in sulbactam
MICs in these strains. In this context, the potent synergy observed between sulbactam and
avibactam indicates that there could be different targets for each DBO.
We were unable to detect a known resistant mechanism compromising sulbactam
activity. Only a small proportion of the strains presented narrow-spectrum or extended
spectrum β-lactamases that affect sulbactam. No mutations in the genes coding for PBPs
were observed in a previously analyzed subset of NDM producers [15]. Taken together,
these results suggest that sulbactam/avibactam synergy could have an effect on other
targets in MDR strains.
We explored the possible contribution in resistance to sulbactam and its interaction
with avibactam of genes related with efflux pumps, two components system, cell wall
synthesis genes. We observed that mrcB and mreB were two key components, in addition to
the coding genes for PBPs, for phenotypic resistance to sulbactam. mrcB, which codes for a
transglycosylase-transpeptidase, and mreB, which codes for cytoskeletal proteins, could
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play a key role in maintaining vital (or alternate) processes in wall synthesis in the presence
of sulbactam, which can explain in part the observed sulbactam MIC reduction when
they are inactivated. Potentiation of sulbactam activity by avibactam is also lost in these
mutant strains, suggesting that conserved mrcB and mreB are a necessary (but not sufficient)
prerequisite for avibactam interactions. More studies to discern the possible interplay of
sulbactam and sulbactam/avibactam on mreB and mrcB are needed. We also identified key
genes that seem necessary to guarantee the interaction between sulbactam and avibactam.
BfmRS, a global regulatory system in Acinetobacter, is a key challenge for antibiotic therapy.
BfmRS per se has been shown to increase the ability of Acinetobacter to grow in the presence
of diverse antibiotics and tolerate transient, high-level antibiotic exposures [37]. As we
observed, avibactam (with sulbactam) may interfere or bypass the normal protection from
β-lactam toxicity mediated by BfmRS. advA (antibiotic susceptibility and division protein
of Acinetobacter) is another essential gene for A. baumannii growth. It has been shown that
reduced AdvA levels modulated antibiotic susceptibility and generate a selective pattern of
hypersensitivity to fluoroquinolones and β-lactams [38]. Avibactam could be a hypothetical
mediator for sulbactam hypersensitivity through advA interaction. Identification of other
genes potentially involved in the interaction between sulbactam and avibactam, such as
XerCD, tyrosine recombinases that catalyze the resolution of dimeric chromosomes [39],
opens up new possibilities in target identification for designing new drug combinations.
In summary, sulbactam/DBOs, especially in combination with avibactam, demon-
strated potent antibacterial activity against recent, geographically diverse clinical isolates
of Acinetobacter, including XDR isolates such as widespread oxacillinase producers. The
addition of a DBO to sulbactam appears to be a very promising strategy for managing
difficult-to-treat Acinetobacter infections. We identified at least 6 genes that could partici-
pate in the interaction of sulbactam with avibactam. Understanding this interaction will
clarify how A. baumannii optimizes its ability to grow under antibiotics exposition. Further
extensive in vitro and in vivo studies have to be performed to confirm the potential use of
these adjuvants as therapeutic alternatives.
4. Materials and Methods
4.1. Bacterial Strains
A representative panel of 187 ESBL-producers and CR Acinetobacter spp. clinical
strains were used to test sulbactam or sulbactam in combination with avibactam or relebac-
tam (Table S1). Among the included strains 152 were A. baumannii, including previously
well-characterized strains such as AB5075, AB0057 and ABUH702 [40–42], and 35 corre-
sponded to non-baumannii species. Among these isolates, 4 were non-ESBL/non-CRAB,
7 were ESBL producing, while 176 were carbapenem-resistant strains. The ATCC 17,978
A. baumannii, ATCC 700,903 Klebsiella pneumoniae, ATCC 25,922 Escherichia coli, and ATCC
35,218 E. coli strains were used as control. In addition, 23 mutant strains from Manoil Lab
(Washington, DC, USA) were used to test sulbactam/avibactam activity. Among them
we selected AB5075∆adeR, AB5075∆bfmR, AB5075∆bfmS, AB5075∆PBPG, AB5075∆advA,
AB5075∆adeB, AB5075∆ampC, AB5075∆OXA-69, AB5075∆adeA, AB5075∆mrdB, AB5075∆mltB,
AB5075∆mrcB, AB5075∆adeK, AB5075∆recA, AB5075∆xerD, AB5075∆xerC, AB5075∆lpxB,
AB5075∆mreB, AB5075∆mreC, AB5075∆mreD, AB5075∆ElsL, AB5075∆dnaK, AB5075∆dksA.
4.2. Antimicrobial Susceptibility Assay
MICs against sulbactam (range 0.12–512 mg/L), sulbactam plus 4 mg/L avibactam
(range 0.12–64 mg/L) and sulbactam plus 4 mg/L relebactam (range 0.12–64 mg/L) were
performed using the reference methods agar dilution according to CLSI Standards [43].
Because breakpoints are available for sulbactam alone, 4 mg/L was applied for this analysis
based on the CLSI susceptible breakpoint of 8/4 mg/L for ampicillin/sulbactam for Acine-
tobacter spp. [44,45]. The in vitro activity of other comparators, such as imipenem, colistin,
tigecycline, amikacin, ceftazidime (alone and in combination with 4 mg/L of avibactam)
were also evaluated by dilution methods at one facility.
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